x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012930
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat, Monkey |
| Applications | WB |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ile259 of human TRXR1 protein. Antibodies are purified by protein A and peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | TXNRD1 |
| UniProt No. | Q16881 |
| Gene ID | 7296 |
| Gene Description | TRXR1 is a selenocysteine-containing protein that is involved in redox homeostasis. Its canonical target is thioredoxin, another redox protein. Together, they are involved in many functions such as antioxidant regulation, cell proliferation, DNA replication, and transcription. TRXR1 is also capable of reducing a wide array of cellular proteins. Selenium deficiency, either by diet modification or introduction of methylmercury, hinders proper expression and function of TRXR1. It is possible that this effect, which results in a higher oxidative state, is a result of the selenocysteine codon being read as a STOP codon in the absence of adequate selenium. The functions of TRXR1 in cell proliferation and antioxidant defense make it a potential therapeutic target. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
